基于网络药理学和体外实验探讨羌活醇通过COX2/WNT/β-catenin轴促进成骨细胞分化的机制OA
Mechanism of notopterol in promoting osteoblast differentiation via the COX2/WNT/β-catenin axis based on network pharmacology and in vitro experiments
本研究基于网络药理学与体外实验探讨羌活醇促进成骨细胞分化的作用机制.通过PubChem、SwissTarget-Prediction等数据库预测羌活醇作用靶点,结合GeneCards、OMIM、CTD数据库获取骨质疏松相关靶点,利用Venny、STRING、Cytoscape等工具构建药物-疾病共同靶点网络,并进行GO功能与KEGG通路富集分析;以小鼠颅顶前骨细胞亚克隆14(MC3T3-E1)和小鼠骨髓间充质干细胞为模型,采用CCK-8法确定羌活醇的安全浓度范围,通过碱性磷酸酶(alkaline phosphatase,ALP)活性检测、茜素红染色、RT-qPCR、Western blot以及使用无翅型MMTV整合位点家族/β-连环蛋白(wingless-type MMTV integration site family/beta-catenin,WNT/β-catenin)信号通路抑制剂 XAV-939 进行验证,评估羌活醇的促成骨分化效应及机制.结果显示,网络药理学筛选出羌活醇与骨质疏松的61个共有靶点,核心靶点包括前列腺素内过氧化物合酶2(prostaglandin-endoperoxide synthase 2,PTGS2)(编码环氧化酶-2(cyclooxy-genase-2,COX2)蛋白)、钾电压门控通道亚家族 A 成员 2(potassium voltage-gated channel subfamily A member 2,KCNA2)、缺氧诱导因子 1α(hypoxia inducible factor 1 subunit alpha,HIF1 A)等;KEGG 分析提示其可能通过 WNT/β-catenin信号通路发挥作用,分子对接表明羌活醇与核心靶点COX2蛋白结合最为稳定(结合能为-8.5 kcal/mol);体外实验证实,在安全浓度(5、10、20 μmol/L)下,羌活醇可显著增强ALP活性、促进钙结节形成,并上调成骨相关基因Runt 相关转录因子 2(Runt-related transcription factor 2,Runx2)、骨特异性转录因子(specificity protein 7,Sp7)和远端缺失同源框5(distal-less homeobox 5,Dlx5)的mRNA表达,Western blot实验进一步表明羌活醇通过上调COX2表达激活 WNT/β-catenin 通路,促进 β-catenin 核转位及下游 G1/S-特异性周期蛋白-D1(G1/S-specific cyclin-D1,Cyclin D1)、B细胞淋巴瘤-2(B-cell lymphoma 2,BCL-2)蛋白表达,该效应可被XAV-939逆转.以上结果提示,羌活醇可能通过调控COX2/WNT/β-catenin信号轴促进成骨细胞分化,为羌活醇在骨质疏松治疗中的应用提供理论依据.
This study aims to investigate the mechanism by which notopterol promotes osteoblast differentiation using network pharmacology and in vitro experiments.The potential targets of notopterol were predicted using databases including PubChem and SwissTargetPrediction.Disease targets related to osteoporosis were retrieved from the GeneCards,OMIM,and CTD data-bases.The Venny,STRING,and Cytoscape tools were utilized to construct a drug-disease common target network and to per-form GO functional enrichment and KEGG pathway enrichment analyses.Mouse calvarial preosteoblast subclone 14(MC3T3-E1)cell and mouse bone marrow mesenchymal stem cell were used as models.The safe concentration range of notopterol was determined using CCK-8 assay.The osteogenic differentiation-promoting effects and underlying mechanisms were evaluated by assessing alkaline phosphatase(ALP)activity,Alizarin Red S staining,RT-qPCR,Western blot,and validation using the wingless-type MMTV integration site family/beta-catenin(WNT/β-catenin)signaling pathway inhibitor XAV-939.The re-sults showed that network pharmacology screening identified 61 common targets between notopterol and osteoporosis.Core tar-gets included prostaglandin-endoperoxide synthase 2(PTGS2)(which encodes the cyclooxygenase-2(COX2)protein),po-tassium voltage-gated channel subfamily A member 2(KCNA2),and hypoxia inducible factor 1 subunit alpha(HIF1A).KEGG analysis suggested a potential role through the WNT/β-catenin signaling pathway.Molecular docking indicated that no-topterol exhibited the most stable binding with the COX2 protein(binding energy:-8.5 kcal/mol).In vitro experiments con-firmed that at safe concentrations(5,10,20 μmol/L),notopterol significantly enhanced ALP activity,promoted calcium nod-ule formation,and upregulated the mRNA expression of osteogenic-related genes Runt-related transcription factor 2(Runx2),transcription factor Sp7(Sp7),and distal-less homeobox 5(Dlx5).Western blot analysis further demonstrated that notopterol activates the WNT/β-caten in pathway by upregulating COX2 expression,promoting β-cateni i n nuclear translocation and the ex-pression of downstream proteins G1/S-specific cyclin-D1(Cyclin D1)and B-cell lymphoma 2(BCL-2).These effects were reversed by XAV-939.The findings suggest that notopterol promotes osteoblast differentiation potentially by regulating the COX2/WNT/β-catenin signaling axis,providing a theoretical basis for the application of notopterol in the treatment of osteo-porosis.
邹文静;刘黄兴;樊晨;叶本贵
西藏大学医学院,拉萨 850000||四川大学华西药学院,成都 610000西藏大学医学院,拉萨 850000西藏自治区人民政府驻成都办事处医院西藏大学医学院,拉萨 850000||四川大学华西药学院,成都 610000
医药卫生
羌活醇成骨分化网络药理学WNT/β-catenin信号通路骨质疏松
notopterolosteogenic differentiationnetwork pharmacologyWNT/β-catenin signaling pathwayosteoporosis
《天然产物研究与开发》 2026 (8)
1816-1826,11
2023年度西藏自治区高新社发领域"揭榜挂帅"项目(XZ202303ZY0007G)西藏自治区科技厅中央引导地方科技成果转移转化项目(XZ202301YD0014C)
评论